NCT03651466View on ClinicalTrials.gov

Safety and Tolerability of GX-G6 in Healthy Male Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

August 31, 2017

Primary Completion Date

June 6, 2018

Study Completion Date

June 28, 2018

Conditions
Diabetes Mellitus
Interventions
DRUG

Gx-G6

Each subject will receive a single dose of either GX-G6 or placebo in randomized fashion.

DRUG

Placebo

Each subject will receive a single dose of either GX-G6 or placebo in randomized fashion.

Trial Locations (1)

89231

NUVISAN, Neu-Ulm

Sponsors

Lead Sponsor

Genexine, Inc.
All Listed Sponsors
lead

Genexine, Inc.

INDUSTRY

NCT03651466 - Safety and Tolerability of GX-G6 in Healthy Male Subjects | Biotech Hunter | Biotech Hunter